Rather than representing a failure of FDA’s accelerated approval process, Ariad Pharmaceuticals Inc.’s halt in sales of its leukemia drug Iclusig (ponatinib) due to increasing rates of cardiovascular-related adverse events should be a reassuring sign to industry that the agency is willing to take calculated risks when faced with an efficacious drug.
That FDA requested ponatinib come off the market pending a benefit/risk re-evaluation less than 11 months after accelerated approval might call into question whether the agency’s super-speedy review, officially clocked at less than three months, led to potential safety
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?